WEBULL
WebtradeDownload

Summit Therapeutics (SMMT) Could Be 47% Undervalued On Lunit And ECOG ACRIN Deals

Simply Wall St · 1d ago

Summit Therapeutics (SMMT) has moved into the spotlight after two fresh alliances. The company is pairing its lead drug ivonescimab with AI pathology from Lunit and a new ECOG-ACRIN Phase II/III cancer trial.

At a share price of $15.80, Summit Therapeutics has had a mixed run, with the 1-day share price return of 6.76% and 90-day gain of 16.78% pointing to stronger recent momentum, while the 1-year total shareholder return is down 9.66% and the 3-year total shareholder return is roughly 7x, suggesting long-term holders have still seen very large gains overall.

See how Summit Therapeutics fits into the broader opportunity and compare it with 34 healthcare AI stocks that are shaping the next wave of AI-driven drug development.

For Summit Therapeutics, that sharp swing higher could signal investors re-rating the business after the Lunit and ECOG-ACRIN deals, or it could simply reflect short term enthusiasm. How does the current valuation compare with that choice?

Most Popular Narrative: 47% Undervalued

Summit Therapeutics is trading at $15.80 against a widely followed fair value view of about $30 per share. This frames the latest rally as a move happening well below that narrative benchmark.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

See why 6 investors see Summit Therapeutics as 47% undervalued.

Result: Fair Value of $30.07 (UNDERVALUED)

Still, the whole Summit Therapeutics story leans heavily on a single drug, and any FDA setback on HARMONi or slower uptake in crowded checkpoint markets could quickly challenge that case for the shares being 47% undervalued.

Find out about the key risks to this Summit Therapeutics narrative.

Another View: What Multiples Say About Summit Therapeutics

The DCF and fair value narratives lean heavily in Summit Therapeutics' favor. P/B tells a very different story. At about 20.1x book value versus 1.8x for the US biotech group and 8.1x for peers, the stock already prices in a lot. If sentiment turns, how quickly could that gap start to compress?

See what the numbers say about this price and find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:SMMT P/B Ratio as at Nov 2026
NasdaqGM:SMMT P/B Ratio as at Nov 2026

Next Steps

Mixed messages on Summit Therapeutics so far, right? If you want to move quickly and judge the setup for yourself, weigh both sides and see the full picture with 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Summit Therapeutics?

Do not stop your research with Summit Therapeutics alone. Broadening your watchlist across other high quality opportunities can sharpen your decisions and highlight better risk reward setups.